Long-term treatment results of hepatoblastoma at a single institution in Taiwan

Jen Yin Hou, Hsi Che Liu, Ting Chi Yeh, Shu Huey Chen, Lin Yen Wang, Jin Cherng Sheu, Der Cherng Liang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

From 1990 to 2004, there were 23 consecutive patients with hepatoblastoma treated at Mackay Memorial Hospital in Taipei, Taiwan. There were 7 patients of stage I, 3 of stage II, 13 of stage III, and none had stage IV disease. Two siblings had congenital hepatoblastoma and both survived. Two patients were prematurity. Beckwith-Wiedemann syndrome, isosexual precocity, chronic B hepatitis presented in 1 patient each. In addition to surgery, we used cisplatin 90 mg/m 2/d on day 1 and epirubicin 25 mg/m 2/d for days 1 to 3 as first-line chemotherapy. Each course was repeated every 3 weeks. Epirubicin was chosen because of its lower cardiotoxicity. Carboplatin/etoposide and vincristine/cyclophosphamide/5-fluorouracil were the second-line chemotherapy for considering cumulative toxicity of first-line chemotherapy. If initial total excision was feasible, postoperative chemotherapy of 4 to 6 courses were given. Three patients died of progressive disease, infection, and relapse 1 each. The median duration of follow-up for 20 survived patients was 94 months. The 5-year event-free and overall survival rates were 73.9%±9.2% (SE) and 87%±7.0%, respectively. Tumor recurred in 5 patients. The commonest toxicity was febrile neutropenia. There was no cardiotoxicity event. In conclusion, with sequential combination of surgery and chemotherapy, the treatment results for hepatoblastoma were satisfactory as compared with other groups.

Original languageEnglish
Pages (from-to)718-722
Number of pages5
JournalJournal of Pediatric Hematology/Oncology
Volume31
Issue number10
DOIs
Publication statusPublished - Oct 2009
Externally publishedYes

Fingerprint

Hepatoblastoma
Taiwan
Drug Therapy
Epirubicin
Therapeutics
Beckwith-Wiedemann Syndrome
Febrile Neutropenia
Carboplatin
Chronic Hepatitis B
Vincristine
Etoposide
Combination Drug Therapy
Fluorouracil
Cyclophosphamide
Cisplatin
Disease-Free Survival
Siblings
Survival Rate
Recurrence
Infection

Keywords

  • Chemotherapy
  • Cisplatin
  • Epirubicin
  • Hepatoblastoma

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Long-term treatment results of hepatoblastoma at a single institution in Taiwan. / Hou, Jen Yin; Liu, Hsi Che; Yeh, Ting Chi; Chen, Shu Huey; Wang, Lin Yen; Sheu, Jin Cherng; Liang, Der Cherng.

In: Journal of Pediatric Hematology/Oncology, Vol. 31, No. 10, 10.2009, p. 718-722.

Research output: Contribution to journalArticle

Hou, Jen Yin ; Liu, Hsi Che ; Yeh, Ting Chi ; Chen, Shu Huey ; Wang, Lin Yen ; Sheu, Jin Cherng ; Liang, Der Cherng. / Long-term treatment results of hepatoblastoma at a single institution in Taiwan. In: Journal of Pediatric Hematology/Oncology. 2009 ; Vol. 31, No. 10. pp. 718-722.
@article{1612f01e8dec4d6d916f090e7223f24f,
title = "Long-term treatment results of hepatoblastoma at a single institution in Taiwan",
abstract = "From 1990 to 2004, there were 23 consecutive patients with hepatoblastoma treated at Mackay Memorial Hospital in Taipei, Taiwan. There were 7 patients of stage I, 3 of stage II, 13 of stage III, and none had stage IV disease. Two siblings had congenital hepatoblastoma and both survived. Two patients were prematurity. Beckwith-Wiedemann syndrome, isosexual precocity, chronic B hepatitis presented in 1 patient each. In addition to surgery, we used cisplatin 90 mg/m 2/d on day 1 and epirubicin 25 mg/m 2/d for days 1 to 3 as first-line chemotherapy. Each course was repeated every 3 weeks. Epirubicin was chosen because of its lower cardiotoxicity. Carboplatin/etoposide and vincristine/cyclophosphamide/5-fluorouracil were the second-line chemotherapy for considering cumulative toxicity of first-line chemotherapy. If initial total excision was feasible, postoperative chemotherapy of 4 to 6 courses were given. Three patients died of progressive disease, infection, and relapse 1 each. The median duration of follow-up for 20 survived patients was 94 months. The 5-year event-free and overall survival rates were 73.9{\%}±9.2{\%} (SE) and 87{\%}±7.0{\%}, respectively. Tumor recurred in 5 patients. The commonest toxicity was febrile neutropenia. There was no cardiotoxicity event. In conclusion, with sequential combination of surgery and chemotherapy, the treatment results for hepatoblastoma were satisfactory as compared with other groups.",
keywords = "Chemotherapy, Cisplatin, Epirubicin, Hepatoblastoma",
author = "Hou, {Jen Yin} and Liu, {Hsi Che} and Yeh, {Ting Chi} and Chen, {Shu Huey} and Wang, {Lin Yen} and Sheu, {Jin Cherng} and Liang, {Der Cherng}",
year = "2009",
month = "10",
doi = "10.1097/MPH.0b013e3181b6db88",
language = "English",
volume = "31",
pages = "718--722",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - Long-term treatment results of hepatoblastoma at a single institution in Taiwan

AU - Hou, Jen Yin

AU - Liu, Hsi Che

AU - Yeh, Ting Chi

AU - Chen, Shu Huey

AU - Wang, Lin Yen

AU - Sheu, Jin Cherng

AU - Liang, Der Cherng

PY - 2009/10

Y1 - 2009/10

N2 - From 1990 to 2004, there were 23 consecutive patients with hepatoblastoma treated at Mackay Memorial Hospital in Taipei, Taiwan. There were 7 patients of stage I, 3 of stage II, 13 of stage III, and none had stage IV disease. Two siblings had congenital hepatoblastoma and both survived. Two patients were prematurity. Beckwith-Wiedemann syndrome, isosexual precocity, chronic B hepatitis presented in 1 patient each. In addition to surgery, we used cisplatin 90 mg/m 2/d on day 1 and epirubicin 25 mg/m 2/d for days 1 to 3 as first-line chemotherapy. Each course was repeated every 3 weeks. Epirubicin was chosen because of its lower cardiotoxicity. Carboplatin/etoposide and vincristine/cyclophosphamide/5-fluorouracil were the second-line chemotherapy for considering cumulative toxicity of first-line chemotherapy. If initial total excision was feasible, postoperative chemotherapy of 4 to 6 courses were given. Three patients died of progressive disease, infection, and relapse 1 each. The median duration of follow-up for 20 survived patients was 94 months. The 5-year event-free and overall survival rates were 73.9%±9.2% (SE) and 87%±7.0%, respectively. Tumor recurred in 5 patients. The commonest toxicity was febrile neutropenia. There was no cardiotoxicity event. In conclusion, with sequential combination of surgery and chemotherapy, the treatment results for hepatoblastoma were satisfactory as compared with other groups.

AB - From 1990 to 2004, there were 23 consecutive patients with hepatoblastoma treated at Mackay Memorial Hospital in Taipei, Taiwan. There were 7 patients of stage I, 3 of stage II, 13 of stage III, and none had stage IV disease. Two siblings had congenital hepatoblastoma and both survived. Two patients were prematurity. Beckwith-Wiedemann syndrome, isosexual precocity, chronic B hepatitis presented in 1 patient each. In addition to surgery, we used cisplatin 90 mg/m 2/d on day 1 and epirubicin 25 mg/m 2/d for days 1 to 3 as first-line chemotherapy. Each course was repeated every 3 weeks. Epirubicin was chosen because of its lower cardiotoxicity. Carboplatin/etoposide and vincristine/cyclophosphamide/5-fluorouracil were the second-line chemotherapy for considering cumulative toxicity of first-line chemotherapy. If initial total excision was feasible, postoperative chemotherapy of 4 to 6 courses were given. Three patients died of progressive disease, infection, and relapse 1 each. The median duration of follow-up for 20 survived patients was 94 months. The 5-year event-free and overall survival rates were 73.9%±9.2% (SE) and 87%±7.0%, respectively. Tumor recurred in 5 patients. The commonest toxicity was febrile neutropenia. There was no cardiotoxicity event. In conclusion, with sequential combination of surgery and chemotherapy, the treatment results for hepatoblastoma were satisfactory as compared with other groups.

KW - Chemotherapy

KW - Cisplatin

KW - Epirubicin

KW - Hepatoblastoma

UR - http://www.scopus.com/inward/record.url?scp=70349811290&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349811290&partnerID=8YFLogxK

U2 - 10.1097/MPH.0b013e3181b6db88

DO - 10.1097/MPH.0b013e3181b6db88

M3 - Article

C2 - 19727010

AN - SCOPUS:70349811290

VL - 31

SP - 718

EP - 722

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 10

ER -